Literature DB >> 10749562

Antagonists to the rescue.

W J Welch1, M Howard.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10749562      PMCID： PMC377489          DOI： 10.1172/JCI9158

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  12 in total

Review 1.  Misfolded proteins in the endoplasmic reticulum.

Authors:  D H Perlmutter
Journal:  Lab Invest       Date:  1999-06       Impact factor: 5.662

Review 2.  Solubility as a function of protein structure and solvent components.

Authors:  C H Schein
Journal:  Biotechnology (N Y)       Date:  1990-04

Review 3.  Cystic fibrosis.

Authors:  P B Davis; M Drumm; M W Konstan
Journal:  Am J Respir Crit Care Med       Date:  1996-11       Impact factor: 21.405

4.  Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators.

Authors:  T W Loo; D M Clarke
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

5.  Correcting temperature-sensitive protein folding defects.

Authors:  C R Brown; L Q Hong-Brown; W J Welch
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

6.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

Authors:  J P Morello; A Salahpour; A Laperrière; V Bernier; M F Arthus; M Lonergan; U Petäjä-Repo; S Angers; D Morin; D G Bichet; M Bouvier
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 7.  Defective protein folding as a basis of human disease.

Authors:  P J Thomas; B H Qu; P L Pedersen
Journal:  Trends Biochem Sci       Date:  1995-11       Impact factor: 13.807

8.  Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency.

Authors:  J A Burrows; L K Willis; D H Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

9.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

Authors:  G M Denning; M P Anderson; J F Amara; J Marshall; A E Smith; M J Welsh
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

10.  Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation.

Authors:  S Sato; C L Ward; M E Krouse; J J Wine; R R Kopito
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157
View more
  7 in total

Review 1.  GnRH signaling, the gonadotrope and endocrine control of fertility.

Authors:  Stuart P Bliss; Amy M Navratil; Jianjun Xie; Mark S Roberson
Journal:  Front Neuroendocrinol       Date:  2010-05-06       Impact factor: 8.606

2.  Alpha(1)-Antitrypsin Deficiency.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-12

Review 3.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

Review 4.  Garrod's foresight; our hindsight.

Authors:  C R Scriver
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

5.  Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o- airway epithelial monolayers.

Authors:  Zsuzsa Bebok; James F Collawn; John Wakefield; William Parker; Yao Li; Karoly Varga; Eric J Sorscher; J P Clancy
Journal:  J Physiol       Date:  2005-10-06       Impact factor: 5.182

Review 6.  Enzyme replacement and enhancement therapies for lysosomal diseases.

Authors:  R J Desnick
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

7.  Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine.

Authors:  Belinda Galeano; Riko Klootwijk; Irini Manoli; MaoSen Sun; Carla Ciccone; Daniel Darvish; Matthew F Starost; Patricia M Zerfas; Victoria J Hoffmann; Shelley Hoogstraten-Miller; Donna M Krasnewich; William A Gahl; Marjan Huizing
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.